title: A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection.
abstract: The US Food and Drug Administration has recently approved a number of new direct-acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug-drug interactions. These interactions must be considered both when starting and stopping any medication, including over-the-counter medications and herbal supplements. These drug-drug interactions can increase the risk of toxicity or decrease the likelihood of treatment response. Knowledge of these interactions is paramount in optimizing the success of antiviral therapy.
  
  
  CONCLUSIONS
  In this review we summarize the available data regarding drug-drug interactions for direct-acting antiviral agents, the interactions being the most clinically relevant that are currently known; this review is intended to serve as a clinician's guide to understanding and managing these complex interactions. (Hepatology 2016;63:634-643).
authors.affiliation: Department of, Pharmacy Intermountain Medical Center, Murray, UT.
authors.forename: Travis B
authors.initials: TB
authors.lastname: Dick
authors.affiliation: Department of, Pharmacy Intermountain Medical Center, Murray, UT.
authors.forename: Lance S
authors.initials: LS
authors.lastname: Lindberg
authors.affiliation: Department of, Pharmacy Intermountain Medical Center, Murray, UT.
authors.forename: Debra D
authors.initials: DD
authors.lastname: Ramirez
authors.affiliation: Department of Transplantation, Intermountain Medical Center, Murray, UT.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Charlton
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D065095:Calcineurin Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D004347:Drug Interactions; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D017410:Practice Guidelines as Topic
chemical_list: D000998:Antiviral Agents; D065095:Calcineurin Inhibitors